Targeting HSV-1 glycoprotein D through riboflavin-mediated photodynamic therapy: Insights from bioinformatics analysis and in vitro evaluation

Introduction: The herpes simplex virus type 1 (HSV-1) causes painful viral lesions in the mucosal and cutaneous areas of the oral cavity as well as the head and neck. photodynamic therapy (PDT) effectively inactivates HSV-1 by targeting multiple structures and molecules without the risk of developin...

Full description

Saved in:
Bibliographic Details
Main Authors: Maryam Pourhajibagher, Sayed Mahdi Marashi, Abbas Bahador
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Photodiagnosis and Photodynamic Therapy
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1572100025002157
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849684769635303424
author Maryam Pourhajibagher
Sayed Mahdi Marashi
Abbas Bahador
author_facet Maryam Pourhajibagher
Sayed Mahdi Marashi
Abbas Bahador
author_sort Maryam Pourhajibagher
collection DOAJ
description Introduction: The herpes simplex virus type 1 (HSV-1) causes painful viral lesions in the mucosal and cutaneous areas of the oral cavity as well as the head and neck. photodynamic therapy (PDT) effectively inactivates HSV-1 by targeting multiple structures and molecules without the risk of developing resistant strains. The most significant factor influencing the antiviral efficacy of PDT is the type of photosensitizer used. Therefore, finding more effective photosensitizers is essential. This study utilizes biological databases and bioinformatics tools to investigate computational simulations, molecular docking, and the in vitro antiviral effects of PDT using riboflavin in combination with a light-emitting diode (LED) against HSV-1. Materials and Methods: The three-dimensional structures of glycoprotein D, the viral attachment protein of HSV-1, were predicted and validated using in silico methods. The physicochemical properties of this protein and the quality of the model were assessed. Molecular docking was performed, followed by the determination of the ADME/Tox profile, pharmacokinetic properties, and drug-likeness characteristics of riboflavin. Changes in viral load following PDT using riboflavin against HSV-1 were assessed by a virus titration assay and quantitative polymerase chain reaction (qPCR). Results: It was determined that riboflavin does not violate Lipinski’s Rule of Five as a widely used guideline that predicts the likelihood of a compound being orally active in humans. Riboflavin was classified as toxicity class 6 (very low toxicity) and was found to be non-toxic to the liver, non-immunotoxic, and non-cytotoxic. Molecular docking studies using the three-dimensional model of glycoprotein D with the riboflavin ligand showed good binding affinity. Additionally, the in vitro results of the study showed that LED-activated riboflavin effectively inhibits HSV-1 replication during PDT, resulting in a significant reduction in viral load (P<0.05). Conclusion: The study’s findings indicate that riboflavin, possessing drug-like characteristics, can successfully engage with glycoprotein D, demonstrating a high binding affinity. Additionally, PDT using riboflavin has been shown to effectively suppress HSV-1 replication. Consequently, riboflavin-mediated PDT, by lowering viral load, emerges as a promising supplementary treatment for HSV-1.
format Article
id doaj-art-b02a2aecf226479aa6235a33eea464d2
institution DOAJ
issn 1572-1000
language English
publishDate 2025-08-01
publisher Elsevier
record_format Article
series Photodiagnosis and Photodynamic Therapy
spelling doaj-art-b02a2aecf226479aa6235a33eea464d22025-08-20T03:23:22ZengElsevierPhotodiagnosis and Photodynamic Therapy1572-10002025-08-015410468310.1016/j.pdpdt.2025.104683Targeting HSV-1 glycoprotein D through riboflavin-mediated photodynamic therapy: Insights from bioinformatics analysis and in vitro evaluationMaryam Pourhajibagher0Sayed Mahdi Marashi1Abbas Bahador2Dental Research Center, Dentistry Research Institute, Tehran University of Medical Sciences, Tehran, IranDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, IranDepartment of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; Corresponding author.Introduction: The herpes simplex virus type 1 (HSV-1) causes painful viral lesions in the mucosal and cutaneous areas of the oral cavity as well as the head and neck. photodynamic therapy (PDT) effectively inactivates HSV-1 by targeting multiple structures and molecules without the risk of developing resistant strains. The most significant factor influencing the antiviral efficacy of PDT is the type of photosensitizer used. Therefore, finding more effective photosensitizers is essential. This study utilizes biological databases and bioinformatics tools to investigate computational simulations, molecular docking, and the in vitro antiviral effects of PDT using riboflavin in combination with a light-emitting diode (LED) against HSV-1. Materials and Methods: The three-dimensional structures of glycoprotein D, the viral attachment protein of HSV-1, were predicted and validated using in silico methods. The physicochemical properties of this protein and the quality of the model were assessed. Molecular docking was performed, followed by the determination of the ADME/Tox profile, pharmacokinetic properties, and drug-likeness characteristics of riboflavin. Changes in viral load following PDT using riboflavin against HSV-1 were assessed by a virus titration assay and quantitative polymerase chain reaction (qPCR). Results: It was determined that riboflavin does not violate Lipinski’s Rule of Five as a widely used guideline that predicts the likelihood of a compound being orally active in humans. Riboflavin was classified as toxicity class 6 (very low toxicity) and was found to be non-toxic to the liver, non-immunotoxic, and non-cytotoxic. Molecular docking studies using the three-dimensional model of glycoprotein D with the riboflavin ligand showed good binding affinity. Additionally, the in vitro results of the study showed that LED-activated riboflavin effectively inhibits HSV-1 replication during PDT, resulting in a significant reduction in viral load (P<0.05). Conclusion: The study’s findings indicate that riboflavin, possessing drug-like characteristics, can successfully engage with glycoprotein D, demonstrating a high binding affinity. Additionally, PDT using riboflavin has been shown to effectively suppress HSV-1 replication. Consequently, riboflavin-mediated PDT, by lowering viral load, emerges as a promising supplementary treatment for HSV-1.http://www.sciencedirect.com/science/article/pii/S1572100025002157Herpes simplex virus type 1Photodynamic therapyRiboflavin, qPCRVirus titration assay
spellingShingle Maryam Pourhajibagher
Sayed Mahdi Marashi
Abbas Bahador
Targeting HSV-1 glycoprotein D through riboflavin-mediated photodynamic therapy: Insights from bioinformatics analysis and in vitro evaluation
Photodiagnosis and Photodynamic Therapy
Herpes simplex virus type 1
Photodynamic therapy
Riboflavin, qPCR
Virus titration assay
title Targeting HSV-1 glycoprotein D through riboflavin-mediated photodynamic therapy: Insights from bioinformatics analysis and in vitro evaluation
title_full Targeting HSV-1 glycoprotein D through riboflavin-mediated photodynamic therapy: Insights from bioinformatics analysis and in vitro evaluation
title_fullStr Targeting HSV-1 glycoprotein D through riboflavin-mediated photodynamic therapy: Insights from bioinformatics analysis and in vitro evaluation
title_full_unstemmed Targeting HSV-1 glycoprotein D through riboflavin-mediated photodynamic therapy: Insights from bioinformatics analysis and in vitro evaluation
title_short Targeting HSV-1 glycoprotein D through riboflavin-mediated photodynamic therapy: Insights from bioinformatics analysis and in vitro evaluation
title_sort targeting hsv 1 glycoprotein d through riboflavin mediated photodynamic therapy insights from bioinformatics analysis and in vitro evaluation
topic Herpes simplex virus type 1
Photodynamic therapy
Riboflavin, qPCR
Virus titration assay
url http://www.sciencedirect.com/science/article/pii/S1572100025002157
work_keys_str_mv AT maryampourhajibagher targetinghsv1glycoproteindthroughriboflavinmediatedphotodynamictherapyinsightsfrombioinformaticsanalysisandinvitroevaluation
AT sayedmahdimarashi targetinghsv1glycoproteindthroughriboflavinmediatedphotodynamictherapyinsightsfrombioinformaticsanalysisandinvitroevaluation
AT abbasbahador targetinghsv1glycoproteindthroughriboflavinmediatedphotodynamictherapyinsightsfrombioinformaticsanalysisandinvitroevaluation